BR9909677A - Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas - Google Patents

Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas

Info

Publication number
BR9909677A
BR9909677A BR9909677-3A BR9909677A BR9909677A BR 9909677 A BR9909677 A BR 9909677A BR 9909677 A BR9909677 A BR 9909677A BR 9909677 A BR9909677 A BR 9909677A
Authority
BR
Brazil
Prior art keywords
antibody
intensification
mediated
administration
fusion protein
Prior art date
Application number
BR9909677-3A
Other languages
English (en)
Inventor
Stephen D Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of BR9909677A publication Critical patent/BR9909677A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"INTENSIFICAçãO DE RESPOSTAS IMUNOLóGICAS, MEDIADAS POR PROTEìNA DE FUSãO ANTICORPO-CITOCINA, ATRAVéS DA CO-ADMINISTRAçãO COM INIBIDOR DE PROSTAGLANDINAS" Descreve-se composições e métodos para intensificar uma resposta imunológica citocida dirigida contra um tipo de célula pré-selecionada em um mamífero. Os métodos e composições baseiam-se em uma combinação de um imunoconjugado anticorpo-citocina e um inibidor de prostaglandinas. Uma vez administrado a um mamífero, o imunoconjugado induz uma resposta imunológica contra o tipo pré-selecionado de célula, como por exemplo, uma célula cancerosa, resposta essa que, como resultado da imunopotenciação por meio do inibidor de prostaglandinas, é maior do que a resposta imunológica induzida pelo imunoconjugado sozinho. Os métodos e composições são particularmente úteis para exterminar tumores sólidos ou células infectadas por vírus em um mamífero.
BR9909677-3A 1998-04-17 1999-04-16 Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas BR9909677A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8216698P 1998-04-17 1998-04-17
PCT/US1999/008376 WO1999053958A2 (en) 1998-04-17 1999-04-16 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor

Publications (1)

Publication Number Publication Date
BR9909677A true BR9909677A (pt) 2000-12-19

Family

ID=22169464

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909677-3A BR9909677A (pt) 1998-04-17 1999-04-16 Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas

Country Status (16)

Country Link
US (1) US20040033210A1 (pt)
EP (1) EP1071469A2 (pt)
JP (1) JP2002512204A (pt)
CN (1) CN1305387A (pt)
AU (1) AU758851B2 (pt)
BR (1) BR9909677A (pt)
CA (1) CA2328081A1 (pt)
CZ (1) CZ20003817A3 (pt)
HK (1) HK1038881A1 (pt)
HU (1) HUP0101343A3 (pt)
MX (1) MXPA00010151A (pt)
NO (1) NO20005186L (pt)
PL (1) PL343486A1 (pt)
RU (1) RU2217168C2 (pt)
WO (1) WO1999053958A2 (pt)
ZA (1) ZA200005477B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体－细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
DE69942207D1 (de) * 1998-08-25 2010-05-12 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU6227400A (en) * 1999-07-26 2001-02-13 Childrens Hospital Los Angeles Research Institute Fenretinide increases antibody cellular toxicity
RU2263118C2 (ru) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DK1252192T3 (da) * 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
SK982003A3 (en) * 2000-06-29 2004-05-04 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7148321B2 (en) * 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
ES2361664T3 (es) * 2001-05-03 2011-06-21 Merck Patent Gmbh Anticuerpo recombinante para tumor específico y su utilización.
AU2002357784B2 (en) * 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
JP4723811B2 (ja) * 2002-03-15 2011-07-13 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 始原肝幹細胞および近位肝幹細胞
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004309050B2 (en) 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
CN1902222A (zh) * 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－***融合蛋白质
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
DE602005016773D1 (de) * 2004-01-22 2009-11-05 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2005313492B2 (en) * 2004-12-09 2011-12-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CN101351475B (zh) * 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
DE3812605A1 (de) * 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
ES2167391T3 (es) * 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
AU3588097A (en) * 1996-07-02 1998-01-21 Bar-Ilan University Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases

Also Published As

Publication number Publication date
EP1071469A2 (en) 2001-01-31
JP2002512204A (ja) 2002-04-23
HUP0101343A2 (hu) 2001-08-28
ZA200005477B (en) 2001-11-20
MXPA00010151A (es) 2002-08-06
US20040033210A1 (en) 2004-02-19
PL343486A1 (en) 2001-08-27
RU2217168C2 (ru) 2003-11-27
CA2328081A1 (en) 1999-10-28
WO1999053958A2 (en) 1999-10-28
AU758851B2 (en) 2003-04-03
CN1305387A (zh) 2001-07-25
NO20005186L (no) 2000-12-14
HUP0101343A3 (en) 2003-10-28
HK1038881A1 (zh) 2002-04-04
AU3566499A (en) 1999-11-08
WO1999053958A3 (en) 1999-12-02
NO20005186D0 (no) 2000-10-16
CZ20003817A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
BR9909677A (pt) Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas
BR9909583A (pt) Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
RU2009138327A (ru) Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака
BRPI0515316A (pt) compostos de imidazoquinolina
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
ES2176502T3 (es) Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion.
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
BR0015491A (pt) Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
BR0308339A (pt) Indazóis substituìdos com uma atividade anticancerosa
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
CY1106541T1 (el) Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης
TR200201244T2 (tr) Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
DE60023660D1 (de) Antizymmodulatoren sowie deren verwendung
BR0208695A (pt) Composições e métodos para a prevenção e tratamento de c ncer humano da próstata
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
PT1085884E (pt) Combinacao de compostos seleniferos com gemcitabina ou mitomicina c
BR0107262C1 (pt) Composição a base de monoterpenos, com efeito, quimiopreventivo e quimioterápico em neoplasias malignas de seres humanos e animais, utilização dos monoterpenos na inbição do crescimento de células tumorais e no controle de metástases de tumores primários e método especìfico de utilização da composição, com efeito, quimiopreventivo e quimioterápico em seres humanos e animais
Gao et al. N-acetylcysteine (NAC) ameliorates Epstein-Barr virus latent membrane protein 1 induced chronic inflammation
BR9910187A (pt) Processo e composição para induzir uma resposta anti-tumor em um paciente mamìfero sofrendo de um tumor
BRPI0618441A2 (pt) vetor adenoviral e método de indução de uma resposta imune contra um aftovìrus em um mamìfero
DE69533873D1 (de) Krebstherapie mit lymphotoxin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/30 (2006.01), A61K 45/06 (2006.0